Islet Cell Antibody-Positive Versus -Negative Phenotypic Type 2 Diabetes in Youth

Does the oral glucose tolerance test distinguish between the two?

Hala T Feyli, MD1,2
Fida Bacha, MD1,2
Neslihan Gungor, MD3
Silva Arslanian, MD1,2

OBJECTIVE — Using the clamp technique, youths with a clinical diagnosis of type 2 diabetes (CDx-type 2 diabetes) and positive pancreatic autoantibodies (Ab+) were shown to have severe impairment in insulin secretion and less insulin resistance than their peers with negative antibodies (Ab-). In this study, we investigated whether oral glucose tolerance test (OGTT)-derived indexes of insulin secretion and sensitivity could distinguish between these two groups.

RESEARCH DESIGN AND METHODS — A total of 25 Ab-, 11 Ab+ CDx-type 2 diabetic, and 21 obese control youths had an OGTT. Fasting and OGTT-derived indexes of insulin sensitivity (including the Matsuda index, homeostasis model assessment [HOMA] of insulin resistance, quantitative insulin sensitivity check index, and glucose-to-insulin ratio) and insulin secretion (HOMA of insulin secretion and 30-min insulinogenic and C-peptide indexes) were used. Glucagon and glucagon-like peptide (GLP)-1 responses were assessed.

RESULTS — Fasting C-peptide and C-peptide-to-glucose ratio, and C-peptide area under the curve (AUC) were significantly lower in the Ab+ CDx-type 2 diabetic patients. Other OGTT-derived surrogate indexes of insulin sensitivity and secretion were not different between the Ab+ versus Ab- patients. GLP-1 during the OGTT was highest in the Ab+ youths compared with the other two groups, but this difference disappeared after adjusting for BMI. Ab+ and Ab- CDx-type 2 diabetes had relative hyperglucagonemia compared with control subjects.

CONCLUSIONS — The clinical measures of fasting and OGTT-derived surrogate indexes of insulin sensitivity and secretion, except for fasting C-peptide and C-peptide AUC, are less sensitive tools to distinguish metabolic/pathophysiological differences. The clamp, between Ab+ and Ab- CDx-type 2 diabetic youths. This underscores the importance of using more sensitive methods and the importance of determining antibody status in obese youths with CDx-type 2 diabetes.

Diabetes Care 33:632–638, 2010

Diabetes in youth is generally classified into two major categories: type 1 diabetes characterized by autoimmune destruction of the pancreatic beta-cells and absolute insulin deficiency and type 2 diabetes characterized by insulin resistance coupled with a nonimmune-mediated beta-cell failure and relative insulin deficiency (1). While type 1 diabetes remains the most common form of childhood diabetes, type 2 diabetes in youth has increased worldwide over the last decade concomitant with the epidemic increase in childhood obesity (2,3). The diagnosis of type 1 versus type 2 diabetes in children relies largely on the clinical presentation with obesity being a major characteristic of children diagnosed with type 2 diabetes (1,2). However, the increasing prevalence of obesity in children, including those newly diagnosed with type 1 diabetes, has made the clinical distinction between the two types of diabetes more difficult (4). Moreover, 10–75% of physician-diagnosed obese youth with type 2 diabetes have islet cell autoantibodies (3,5–7), which is the hallmark of autoimmune type 1 diabetes. In a previous study using the hyperinsulineemic-euglycemic and the hyperglycemic clamp, we demonstrated important distinguishing features in insulin sensitivity and secretion between antibody-positive (Ab+) versus -negative (Ab-) obese youth with a clinical diagnosis of type 2 diabetes (CDx-type 2 diabetes). While insulin sensitivity was severely impaired in Ab- but not Ab+ patients, beta-cell function was almost completely abolished in Ab+ and not Ab+ type 2 diabetes (8). Moreover, the Ab- CDx-type 2 diabetic patients had features consistent with the metabolic syndrome. These pathophysiological differences have important bearing on the management of diabetes and highlight the importance of making the correct diagnosis. While the clamp technique is considered the gold standard for studying in vivo insulin secretion and sensitivity, its use is limited to the research setting. Therefore, in this study, we investigated whether the oral glucose tolerance test (OGTT), a clinically applicable tool, could be used to distinguish the differences in insulin sensitivity and secretion between the two groups of patients with phenotypic type 2 diabetes versus obese control subjects with normal glucose tolerance.

RESEARCH DESIGN AND METHODS — Thirty-six obese adolescents, all reported previously (8), with CDx-type 2 diabetes diagnosis made by the attending endocrinologist based on the American Diabetes Association diagnostic criteria (1), were recruited from the
Diabetes Center at the Children’s Hospital of Pittsburgh. Islet cell antibody screening revealed 23 with negative antibodies and 11 with positive antibodies. Islet cell antibodies were tested using the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)-sponsored harmonization assay. The control group consisted of 21 age-matched obese, otherwise healthy, adolescents recruited from the community. All study participants were pubertal. The treatment modalities at the time of the study and the characteristics of the study population are summarized in Table 1. None of the obese control subjects were on medications that affect blood glucose metabolism. All studies were approved by the University of Pittsburgh Institutional Review Board, and consents and assents were obtained prior to the investigation.

### Autoantibody testing
GAD 65 kDa autoantibody (GAD65 Ab) and insulinoma-associated protein 2 autoantibody (IA2) were measured using a standardized assay protocol and a common serum calibrator developed by the NIDDK-sponsored standardization group. Results are expressed as DKU/ml. Based on analysis of 550 samples, the cutoff values for positivity/negativity are 33 DKU/ml for GAD65 and 5 DKU/ml for IA2. The calculated assay specificity is 97 USDK/ml for GAD65 and 5 USDK/ml for IA2. The calculated assay sensitivity is 76 and 64, respectively. For GAD65 and 99 for IA2, while the sensitivity is 76 and 64, respectively.

### Biochemical measurements
Plasma glucose was measured with a glucose analyzer (Yellow Springs Instrument, Yellow Springs, OH). Insulin, C-peptide, glucagon, leptin, and adiponectin were measured using radioimmunoassay as before (9). One Ab− patient had high levels of nonspecific binding in the insulin radioimmunoassay, and her insulin data were not included in this analysis. A1C was measured by high-performance liquid chromatography (Tosoh Medics) (9). GLP-1 was measured in 22 CDx-type 2 diabetic and 14 control subjects who had plasma samples collected in tubes containing dipeptidyl peptidase-4 inhibitor (Millipore, St. Charles, MO). Serum GLP-1 was measured on the Luminex 200 IS (Luminex, Austin, TX) using a one-plex human endocrine hormone MILLiplex Kit (catalog no. HENDO-65K-01; Millipore). This assay specifically detects GLP-1 (7–36) amide and GLP-1 (7–37), with no detectable cross-reactivity with GLP-2, GLP-1 (9–36), or glucagon. In our laboratory, the inter- and intra-assay coefficients of vari-

### Table 1—Participants’ demographics and fasting laboratory data

| Cliniically diagnosed type 2 diabetes | Obese control subjects | Post hoc P (Ab+ vs. Ab−)* |
|--------------------------------------|------------------------|---------------------------|
| n | Ab− | Ab+ | ANOVA P | |
| Age (years) | 15.1 ± 0.4 | 14.0 ± 0.7 | 14.5 ± 0.3 | 0.23 | 0.3 |
| Sex (male/female) | 12/13 | 5/6 | 8/13 | 0.79† |
| Ethnicity (African American/white) | 13/12 | 5/6 | 12/9 | 0.82† |
| Tanner (n)† | II–III | 23 | 8 | 18 |
| IV–V | 2 | 3 | 3 |
| BMI (kg/m²) | 36.4 ± 1.1 | 30.4 ± 1.3 | 36.5 ± 1.1 | 0.005 | 0.008 |
| BMI (%) | 98.8 ± 0.2 | 96.5 ± 1.2 | 98.7 ± 0.4 | 0.008 | 0.01 |
| BMI Z score | 2.39 ± 0.1 | 1.99 ± 0.1 | 2.35 ± 0.1 | 0.005 | 0.005 |
| Waist circumference (cm) | 108.6 ± 2.8 | 92.4 ± 3.6 | 104.2 ± 2.8 | 0.006 | 0.004 |
| Percent body fat (%) | 41.2 ± 1.4 | 39.6 ± 2.5 | 44.3 ± 1.0 | 0.1 | 1.0 |
| Visceral adipose tissue (cm²) | 85.6 ± 8.6 | 52.0 ± 6.9 | 59.2 ± 4.1 | 0.006 | 0.019 |
| Subcutaneous abdominal adipose tissue (cm²) | 532.7 ± 29.5 | 432.8 ± 42.1 | 517.0 ± 38.6 | 0.2 | 0.24 |
| A1C (%) | 5.7 ± 0.2 | 6.3 ± 0.3 | 5.4 ± 0.1 | <0.001 | 0.78 |
| Diabetes duration (months) | 8.2 ± 2.3 | 4.5 ± 1.4 | NA | 0.3 |
| Treatment modality n (%)† | Lifestyle | 7 (28) | 2 (18) | NA |
| Insulin | 3 (12) | 1 (9) | NA |
| Metformin | 10 (40) | 1 (9) | NA |
| Insulin and metformin | 5 (20) | 7 (64) | NA |
| Plasma-to-insulin ratio | 0.25 ± 0.03 | 0.21 ± 0.08 | 0.28 ± 0.05 | 0.59 | 1.0 |
| Leptin (ng/ml) | 31.6 ± 2.9 | 23.3 ± 4.0 | 42.6 ± 3.8 | 0.004 | 0.37 |
| Adiponectin (µg/ml) | 5.2 ± 0.6 | 7.1 ± 1.6 | 6.3 ± 0.4 | 0.25 | 0.34 |
| Leptin-to-adiponectin ratio | 8.9 ± 1.6 | 4.1 ± 0.9 | 7.9 ± 1.3 | 0.13 | 0.14 |

Data are means ± SE. *Post hoc Bonferroni correction for Ab− versus Ab+ type 2 diabetic patients. †χ² analysis. NA, not applicable.

*Table 1—Participants’ demographics and fasting laboratory data*
Antibody status, OGTT, and β-cell function

Table 2—Fasting and OGTT-derived surrogate indexes of insulin sensitivity and secretion in Ab− vs. Ab+ clinically diagnosed type 2 diabetic patients and obese control subjects

| Clinically diagnosed type 2 diabetes | Obese control subjects | ANCOVA P (Ab+ vs. Ab−)* |
|-------------------------------------|------------------------|--------------------------|
| Ab− | Ab+ | Anabolic insulin resistance (AIC) was calculated as before (12,13). The AIC at the time of the study was comparable between the Ab+ and the Ab− CDx-type 2 diabetic and higher than obese control subjects. Diabetes duration was similar between the two groups of CDx-type 2 diabetic patients. More Ab− patients tended to be on metformin and lifestyle intervention than Ab+ patients. All subjects in the obese control group had normal glucose tolerance as defined by World Health Organization and American Diabetes Association criteria (1).

Fasting and OGTT glucose, insulin, and C-peptide

Fasting glucose and insulin were not significantly different among the three groups (Ab+, Ab−, and control subjects) was performed using univariate ANCOVA with post hoc Bonferroni correction. A three-way repeated-measures analysis was used to compare glucose, insulin, C-peptide, glucagon, and GLP-1 responses during the OGTT among the three groups with time as a factor. ANCOVA and repeated-measures analyses were adjusted for BMI. Categorical variables were compared using the χ² analysis. A P value of ≤0.05 was considered statistically significant. All values are reported as means ± SE.

RESULTS

Study participants

The clinical and physical characteristics of the study participants are summarized in Table 1. There were no significant differences in age, sex, Tanner stage, and ethnicity among the groups. The Ab+ patients had significantly lower BMI, BMI percentile, Z score, waist circumference, and visceral adipose tissue compared with their Ab− peers and the obese control subjects. AIC at the time of the study was comparable between the Ab+ and the Ab− CDx-type 2 diabetic and higher than obese control subjects. Diabetes duration was similar between the two groups of CDx-type 2 diabetic patients. More Ab− patients tended to be on metformin and lifestyle intervention than Ab+ patients. All subjects in the obese control group had normal glucose tolerance as defined by World Health Organization and American Diabetes Association criteria (1).

Fasting and OGTT glucose, insulin, and C-peptide

Fasting glucose and insulin were not significantly different among the three groups (Ab+, Ab−, and control subjects) was performed using univariate ANCOVA with post hoc Bonferroni correction. A three-way repeated-measures analysis was used to compare glucose, insulin, C-peptide, glucagon, and GLP-1 responses during the OGTT among the three groups with time as a factor. ANCOVA and repeated-measures analyses were adjusted for BMI. Categorical variables were compared using the χ² analysis. A P value of ≤0.05 was considered statistically significant. All values are reported as means ± SE.

RESULTS

Study participants

The clinical and physical characteristics of the study participants are summarized in Table 1. There were no significant differences in age, sex, Tanner stage, and ethnicity among the groups. The Ab+ patients had significantly lower BMI, BMI percentile, Z score, waist circumference, and visceral adipose tissue compared with their Ab− peers and the obese control subjects. AIC at the time of the study was comparable between the Ab+ and the Ab− CDx-type 2 diabetic and higher than obese control subjects. Diabetes duration was similar between the two groups of CDx-type 2 diabetic patients. More Ab− patients tended to be on metformin and lifestyle intervention than Ab+ patients. All subjects in the obese control group had normal glucose tolerance as defined by World Health Organization and American Diabetes Association criteria (1).
between Ab− and Ab+ patients. C-peptide levels were significantly different among the three groups (P < 0.001) and was highest in Ab− versus Ab+ (P < 0.001), with no significant difference between the Ab+ patients and the obese control subjects. Because glucose levels differed during the OGTT among the three groups, C-peptide levels relative to glucose levels are depicted as the C-peptide-to-glucose ratio. C-peptide AUC differed significantly among the three groups and was highest in control subjects and lowest in Ab− patients, with significant differences between the Ab− and Ab+ patients (P = 0.001). The glucose AUC was highest in the Ab+ patients (P < 0.001) and significantly higher than Ab− patients (P < 0.001) (Fig. 1G). C-peptide AUC was significantly lower in the Ab+ compared with the Ab− patients and

care.diabetesjournals.org
obese control subjects, with no difference between the latter two. C-peptide AUC relative to glucose AUC (Fig. 1) was significantly different among the three groups (0.16 ± 0.007, 0.049 ± 0.004, and 0.074 ± 0.004 ng/ml per mg/dl), with significant differences between Ab+ and Ab− patients (P < 0.001).

**Fasting and OGTT-derived indexes of insulin sensitivity**

Fasting glucose–to–insulin ratio, HOMA-IR, WBISI_Matuda, QUICKI, ISI_Cederholm, ISI_Gutt, and ISI_Avignon were significantly different among the three groups, while ISI_stumvoll was not. None of these indexes, however, were significantly different between Ab− and Ab+ CDx-type 2 diabetes (Table 2).

**Fasting and OGTT-derived indexes of insulin secretion**

Fasting C-peptide–to–glucose ratio, 30-min insulinogenic index, ΔI_{30}/ΔG_{30}, and ΔC-Pep_{30}/ΔG_{30} were significantly different among the three groups, but HOMA-%β was not. Fasting C-peptide–to–glucose ratio was significantly lower in the Ab+ versus Ab− patients with and without adjustment for BMI, with no significant differences in HOMA-%β, ΔI_{30}/ΔG_{30}, and ΔC-Pep_{30}/ΔG_{30} (Table 2).

**GLP-1 and glucagon responses during the OGTT**

A subset of participants (13 Ab−, 9 Ab+, and 14 obese control subjects) had GLP-1 data. GLP-1 response and AUC during the OGTT were significantly different among the three groups and highest in Ab+ patients (Fig. 1E and K). However, this difference disappeared after adjusting for BMI (Fig. 1E).

The glucagon levels (Fig. 1F) and AUC (7,233 ± 587 vs. 6,150 ± 590 and 5,366 ± 713 pg·ml−1·min−1 in Ab−, Ab+, and obese control subjects, respectively; P = 0.1) during the OGTT were not different among the three groups. However, when corrected for prevailing glucose levels during the OGTT (glucagon AUC × glucose AUC) the glucagon levels were lowest in the control subjects compared with the two groups of diabetic subjects despite adjustment for BMI (Fig. 1L).

**Adiponectin, leptin, and proinsulin**

Leptin was significantly different among the three groups and lowest in Ab+ patients versus obese control subjects before (P = 0.004) and after (P = 0.03) adjusting for BMI. Adiponectin, leptin-to-adiponectin ratio, and proinsulin-to-insulin ratio were not different among the three groups (Table 1).

**CONCLUSIONS** — The childhood obesity epidemic has resulted in increasing numbers of youth presenting with type 2 diabetes, but, in addition, type 1 diabetic children have become overweight/obese (1,4). This has made the proper clinical distinction between obese type 1 versus type 2 diabetes challenging, especially when a significant number of physician diagnosed obese youth with type 2 diabetes have circulating β-cell autoantibodies (3,5–7). In the present study, even though the Ab+ youth were statistically significantly less obese than the Ab− ones, from a clinical significance perspective they were still very obese.

In a previous publication using the state-of-the-art methodology of the clamp, we reported severe impairment in insulin secretion in Ab+ subjects with CDx-type 2 diabetes in contrast to severe impairment in insulin action in the Ab− patients (8). The current study investigated whether the OGTT, a clinically applicable tool, could reveal differences in insulin secretion and sensitivity in Ab+ versus Ab− patients to assist in the diagnosis of the type of diabetes. Our data show that fasting C-peptide, fasting C-peptide–to–glucose ratio, and C-peptide AUC during the OGTT are significantly lower in Ab+ versus Ab− CDx-type 2 diabetic youths, while none of the other parameters are different. Particularly, none of the sensitivity indexes could distinguish between Ab+ and Ab− CDx-type 2 diabetes.

In our previous study, using the hyperinsulinemic-euglycemic clamp, we demonstrated that insulin sensitivity was significantly lower, ~45% in Ab− versus Ab+ patients (8). In the current 25 Ab− and 11 Ab+ patients, first-phase insulin and C-peptide were significantly different (77.1 ± 10.2 vs. 38.4 ± 4.2 μU/ml, P = 0.001; 5.7 ± 0.4 vs. 2.4 ± 0.3 ng/ml, respectively; P < 0.001). However, neither the ΔI_{30}/ΔG_{30} nor ΔC-Pep_{30}/ΔG_{30} were significantly different between the two groups of type 2 diabetic youths (Table 2). This, again, may be due to the fact that during the hyperglycemic clamp, the insulin response is standardized to the same glucose stimulus in all patients (~225 mg/dl), while this is not the case during the OGTT, where glucose levels are highly variable. There are no prior studies comparing insulin secretion during the OGTT in Ab− versus Ab+ young CDx-type 2 diabetic patients. Studies
from adults with islet cell antibody–positive LADA showed that fasting and stimulated C-peptide levels were reduced compared with islet cell antibody–negative type 2 diabetic patients (17), consistent with our findings. Similarly HOMA-%β was not different between Ab+ and Ab− patients. In normal children, the reported correlations of HOMA-%β with clamp-derived first-phase insulin secretion range between 0.54 and 0.82 depending on the pubertal stage and glucose tolerance status (13,18). Furthermore, HOMA-%β, fasting insulin, and fasting insulin/glucose are reported not to perform well in detecting differences in insulin secretion in adolescents with impaired glucose tolerance (13). Therefore, it is not surprising that OGTT-derived indexes of insulin secretion were not sensitive enough to detect differences in insulin secretion between Ab+ and Ab− Cx-type 2 diabetes in the current study.

Studies comparing Ab− versus Ab+ young patients with phenotypic type 2 diabetes mostly explored the differences in clinical characteristics at presentation (3,5–7), and none evaluated the differences in metabolic responses during the OGTT between the two groups. In the current study, glucose AUC was significantly higher and C-Peptide AUC, per se, or relative to prevailing glucose levels was significantly lower in Ab+ versus Ab− diabetic youth. This is consistent with a preliminary report from the multicenter study Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) that found a tendency for lower fasting C-peptide levels in 48 Ab+ patients compared with 357 Ab− patients (7). In contrast, another study from Europe reported no differences in C-peptide or glucose levels at manifestation between a group of 82 Ab− and a group of 46 Ab+ youth with CDx-type 2 diabetes (6). Another study from the U.S. did not find significant differences in fasting C-peptide levels between 24 GAD-negative young type 2 diabetic patients compared with 24 obese control subjects (5). The observation that C-Peptide AUC/glucose AUC during the OGTT is significantly lower in Ab+ versus Ab− patients may be a helpful metabolic marker, besides the fasting C-peptide, to distinguish Ab+ and Ab− youths with type 2 diabetes. Despite the lack of statistical significance in the differences in treatment modalities between the Ab+ and Ab− patients in our current study; treatment with metformin versus insulin may have affected the interpretation of the fasting and OGTT-derived indexes of insulin secretion and sensitivity.

Relative hyperglucagonemia is shown in adults with type 2 diabetes and with LADA who had higher glucagon concentrations and less suppression of glucagon with hyperglycemia compared with control subjects (14). In the present study, there was evidence of hyperglucagonemia relative to the prevailing glycemia in CDx-type 2 diabetic patients compared with control subjects consistent with data from adult patients (14).

GLP-1 response during the OGTT was not different between Ab− CDx-type 2 diabetic patients and obese control subjects. Plasma levels of GLP-1 are reported to be unaltered (19), reduced (20,21), or elevated (22) in adults with type 2 diabetes. Furthermore, the duration and the severity of diabetes control and the degree of obesity were shown to be independently associated with GLP-1 responses (23), potentially accounting for the literature-reported divergent findings. No significant differences in GLP-1 responses were detected in adults with type 2 diabetes of short duration (3.2 ± 2.8 years) and with relatively good glycemic control (A1C 6.8 ± 0.9%) compared with subjects with impaired glucose tolerance and control subjects (19). Our similar findings of no significant differences in GLP-1 levels between Ab− and obese control subjects are most likely related to the short duration of diabetes (7.3 ± 1.5 months) and well-controlled glycaemia (Table 1). In adults with type 1 diabetes, GLP-1 responses are reported to be normal (20) or reduced compared with control subjects (21). Furthermore, BMI has been shown to correlate inversely with GLP-1 (19,23). Among the subset of patients who had GLP-1 evaluation, the Ab+ group had significantly lower BMI compared with the other two groups. This could explain the observed higher GLP-1 levels in the former group, which disappeared after adjusting for BMI differences.

Last but not least, the observation of significantly lower leptin levels in Ab+ youths compared with control subjects is likely due to the severe insulin deficiency (24). We have shown that in newly diagnosed patients with type 1 diabetes insulin deficiency is associated with low leptin levels and insulin therapy within days corrects this deficiency before any changes in weight are observed (24).

In conclusion, fasting and OGTT-derived surrogate measures of insulin sensitivity and secretion, with the exception of fasting C-peptide and OGTT C-peptide AUC/glucose AUC, are not sufficiently sensitive to detect the significant differences in insulin sensitivity and β-cell function demonstrated by the clamp technique between the two groups of CDx-type 2 diabetic patients. This underscores the importance of using sensitive methods for assessment of β-cell function and insulin sensitivity in pathophysiologic studies. Although relatively small sample sizes may be a limitation of our study, this resonates with the clinical relevance of our findings in that the clinician cannot use fasting or OGTT-derived parameters reliably in distinguishing the individual Ab+ from the Ab− patient. As the presence of autoimmunity implies progressive decline in β-cell function (25), our findings also highlight the importance of determining antibody status in obese pediatric patients with phenotypic type 2 diabetes.
Antibody status, OGTT, and β-cell function

Waistfelder B. Incidence of diabetes in youth in the United States. JAMA 2007; 297:2716–2724.

4. Libman IM, Pietropaolo M, Arslanian SA, LaPorte RE, Becker DJ. Evidence for heterogeneous pathogenesis of insulin-treated diabetes in black and white children. Diabetes Care 2003;26:2876–2882.

5. Umpaichitra V, Banerji MA, Castells S. Autoantibodies in children with type 2 diabetes mellitus. J Pediatr Endocrinol Metab 2002;15(Suppl. 1):525–530.

6. Reinehr T, Schober E, Wiegand S, Thon A, Holl R, the DPV-Wiss Study Group. Beta-cell autoantibodies in children with type 2 diabetes mellitus: subgroup or misclassification? Arch Dis Child 2006; 91:473–477.

7. Klingensmith GJ, Coombs LP, Arslanian S, Copeland K, Cuttler L, Haffner S, Kaufman F, LaffeI L, Linder B, Marcovina SM, Tollefsen SE, Weinstock RS, the TODAY Study Group. Autoantibody positivity in subjects screened for participation in a treatment trial for type 2 diabetes in youth (Abstract). Diabetes 2006;55(Suppl. 1): A67.

8. Tfayli H, Bacha F, Gungor N, Arslanian A. Phenotypic type 2 diabetes in obese youth: insulin sensitivity and secretion in islet-cell antibody negative vs. antibody positive patients. Diabetes 2009;58:738–744.

9. Gungor N, Bacha F, Saad R, Janosky J, Arslanian SA. Youth type 2 diabetes: insulin resistance, β-cell failure, or both? Diabetes Care 2005;28:638–644.

10. Soonthornpun S, Setasuban W, Thanprasit A, Chayanunnukul W, Rattarasarn C, Geater A. Novel insulin sensitivity index derived from oral glucose tolerance test. J Clin Endocrinol Metab 2003; 88:1019–1023.

11. Avignon A, Boegner C, Mariano-Goulart D, Colette C, Monnier L. Assessment of insulin sensitivity from plasma insulin and glucose in the fasting or post oral glucose-load state. Int J Obes Relat Metab Disord 1999;23:512–517.

12. Bacha F, Gungor N, Arslanian SA. Measures of beta-cell function during the oral glucose tolerance test, liquid mixed-meal test, and hyperglycemic clamp test. J Pediatr 2008;152:618–621.

13. Gungor N, Saad R, Janosky J, Arslanian S. Validation of surrogate estimates of insulin sensitivity and insulin secretion in children and adolescents. J Pediatr 2004; 144:47–55.

14. Carlsson A, Sundkvist G, Group L, Tuomi T. Insulin and glucagon secretion in patients with slowly progressing autoimmune diabetes (LADA). J Clin Endocrinol Metab 2000;85:76–80.

15. Zinman B, Kahn SE, Haffner SM, O’Neill MC, Heise MA, Freed MI, the ADOPT Study Group. Phenotypic characteristics of GAD antibody-positive recently diagnosed patients with type 2 diabetes in North America and Europe. Diabetes 2004;53:3193–3200.

16. O’Gorman DJ, Yousif O, Dixon G, McQuaid S, Murphy E, Rahman Y, Gasparro D, Pacini G, Newsholme P, Nolan JJ. In vivo and in vitro studies of GAD antibody-positive subjects with type 2 diabetes: a distinct sub-phenotype. Diabetes Res Clin Pract 2008;80:365–370.

17. Stenstro¨m G, Gottsa¨ter A, Bakhtadze E, Carlsson A, Sundkvist G, Groop L, Tuomi T. Latent autoimmune diabetes in adults: definition, prevalence, β-cell function, and treatment. Diabetes 2005;54(Suppl. 2):S68–S72.

18. Uwaifo GI, Fallon EM, Chin J, Elberg J, Parikh SJ, Yanovski JA. Indices of insulin action, disposal, and secretion derived from fasting samples and clamps in normal glucose-tolerant black and white children. Diabetes Care 2002;25:2081–2087.

19. Vollmer K, Holst JJ, Baller B, Ellrichmann M, Nauck MA, Schmidt WE, Meier JJ. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes 2008;57:678–687.

20. Vilsbøll T, Krarup T, Sonne J, Madsbad S, Volum A, Juul AG, Holst JJ. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab 2003;88:2706–2713.

21. Lugari R, Dell’Anna C, Ugolotti D, Dei Cas A, Barilli AL, Zandomeneghi R, Marani B, Iotti M, Orlandini A, Gnudi A. Effect of nutrient ingestion on glucagon-like peptide 1 (7–36 amide) secretion in human type 1 and type 2 diabetes. Horm Metab Res 2000;32:424–428.

22. Orskov C, Jeppesen J, Madsbad S, Holst JJ. Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. J Clin Invest 1991;87:415–423.

23. Muscelli E, Mari A, asolano A, Camastra S, Seghieri G, Gastaldelli A, Holst JJ, Ferrannini E. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes 2008;57:1340–1348.

24. Hanaki K, Becker DJ, Arslanian S. Leptin before and after insulin therapy in children with new onset type 1 diabetes. J Clin Endocrinol Metab 1999;84:1524–1526.

25. Turner R, Stratton I, Horton V, Manley S, Zimmet P, Mackay IR, Shattock M, Bottazzo GF, Holman R. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes: UK Prospective Diabetes Study Group. Lancet 1997;350:1288–1293.